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Background: Obstructive sleep apnea syndrome (OSAS) is strongly associated with the increasing prevalence of
cerebrovascular events and metabolic syndrome. A growing number of studies have shown OSAS is an independent
factor for insulin resistance, glucose intolerance and type2 diabetes. However, relationship of OSAS with dysglycemia is
complex and still remains poorly understood. Glucose transporter 4 (GLUT4) gene is Human and rodents’ main glucose
transporter sensitive to insulin, and therefore confirmation of candidate gene polymorphisms and association with OSAS
is needed. Aim of our study was to assess whether GLUT4 gene polymorphisms are associated with OSAS.
Methods: Patients hospitalized at People’s Hospital of Xinjiang were selected from January to December 2010. A
total of 568 Han subjects who possibly exist OSAS base on a history and physical examination were completed
the polysomnography, 412of whom (72.5%) were diagnosed with OSAS, and 156 individuals were confirmed without
OSAS (27.5%). 96 severe OSAS patients chosen from OSAS were used for DNA sequencing in functional domain. Blood
samples were collected from all subjects and genotyping was performed on DNA extracted from blood cells.
Results: We performed GLUT4 genome sequencing, found 4 mutated sites. And finally selected three mutated sites
such as rs5415, rs4517 and rs5435, according to principle of linkage disequilibrium (r2 > 0.8) and minimum gene allele
frequency > 5%. All SNPs satisfied HEW (P > 0.05). Our study demonstrated a significant association of GLUT4 SNPrs5417
allele with OSAS, compared with controls (P < 0.05). Haplotype H1 (TCC) and H3 (CCC) defined as SNPrs5415, rs4517 and
rs5435 are marginally associated with OSAS (P < 0.05). Frequencies of C haplotype of rs5417 in OSAS were higher than in
controls. After adjustment for confounding factors, (AC + AA) genotype significantly reduces prevalence of OSAS,
compared with CC genotype. Level of awake blood oxygen and lowest blood oxygen of (AA + AC) genotype was
significantly superior to those of CC genotype.
Conclusions: Our study demonstrates GLUT4 gene SNPrs5417 is associated with OSAS in hypertensive population.
Carriers of AA + AC have less prevalence of obstructive sleep apnea syndrome than that of CC carriers.
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OSAS is defined as coexistence of excessive daytime sleepi-
ness with irregular breathing at night due to complete or
partial closure of upper airways [1,2]. OSAS is estimated to
affect 2-4% of adult population worldwide [3]. All compo-
nents of Metabolic syndrome, including hypertension [4,5],
insulin resistance(IR) [6,7], and low HDL-C, together
with high levels of TG [8,9] are frequent in patients with
OSAS. In this context, OSAS was considered a “mani-
festation of MetS” [10]. Recently, American academy of
Sleep Medicine (AASM) in "Sleep2013: the united asso-
ciation of professional sleep the 27th annual meeting",
recommended all individuals with type 2 diabetes
mellitus and hypertension evaluate their have sleep con-
ditions [11]. However, relationship of OSAS with dys-
glycemia is unclear. There have been accumulating
evidences suggesting OSAS and IR are independently
associated [12,13], considering mechanisms such as
activations of sympathetic nervous system, hypothal-
amic-pituitary axis, sleep fragmentation and changes in
inflammatory pathways in OSAS [14,15]. GLUT4 is
expressed most prominently in adipocytes, skeletal
muscles, and myocardiocytes, where it functions as
so-called insulin-responsive glucose transporter [16].
Closely associated with insulin resistance and type 2
diabetes mellitus(DM), decrease in GLUT4 expression
in cells and inhibition of its transposition are important
factors causing dysglycemia [17,18]. Muscle contraction
and hypoxia are believed to activate glucose transportation
by a calcium-mediated mechanism [19,20]. However, so
far, progress in determining genotypes of OSAS is af-
fected by lack of a consistent definition of phenotype
[21], especially at the part of dysglycemia. This study
hypothesized indirectly, from molecular genetic mecha-
nisms that OSAS causes dysglycemia phenotype, that
OSAS might be associated with GLUT4 gene poly-
morphism through GLUT4 gene mutation locus from
sequencing screening. We aim to provide new ideas for
control of risk factors for cardiovascular diseases from
molecular genetics aspects.
Results
GLUT4 genetic sequence and based typing
Our study found four locus in GLUT4 gene of 96 subjects
with severe OSAS, according to linkage disequilibrium
(LD) (r2 > 0.8) and minimum gene allele frequency > 5%.Table 1 GLUT4 genetic sequence and based typing
SNPs LD Region Allele 1 freq Allele 2 freq The
573C/T promoter 0.72 0.23 TGT
9A/C a Exon 1 0.35 0.65 CCC
A/G a Exon 1 0.35 0.65 TGC
2070C/T Exon 4 0.64 0.36 GCCRepresentative locus are SNPrs5415, rs5417 and rs5435
(Shown in Table 1).
Characteristics of recruited subjects
Case group included 412 hypertensive subjects with OSAS,
mean age (46.31 ± 9.99), gender distribution (80.8% male);
control group encompassed 156 hypertensive subjects with-
out OSAS, mean age (42.15 ± 8.81), gender distribution
(66.7% male). There is statistically significant difference in
age, BMI, neck circumference, abdominal circumference,
Hypersensitive c-reactive protein, fasting glucose, tri-
glycerides, total cholesterol /high-density lipoprotein
cholesterol, apnea hypopnea index (AHI), awakening
respiratory index, index of periodic leg movement, aver-
age heart rate, average duration of obstructive apneas,
average blood oxygen saturation and minimal blood
oxygen saturation, and frequency of Oxygen saturation
decreasing more than 5% or higher between two groups
(P <0.05) (Shown in Table 2).
Comparison of glucose from OGTT and insulin releasing
between two groups
Of 568 subjects, 374 were confirmed to have no DM,
whereas 194 subjects had FPG >5.6 mmol/L after fasting
12 h, to 164 of whom OGTT and insulin releasing test
were conducted according to their acceptance. Figure 1
presents oral glucose tolerance curve, and statistical sig-
nificance was found to exist in FPG of two groups (5.35 ±
1.4 > 5.1 ± 1.0,P = 0.012); FPG of OSAS group was higher
than that of control group. Although OGTT was taken
at four time points (30 min, 60 min, 120 min, 180 min),
no statistical significance was found between two groups
(P > 0.05); however curve contained tendency to be higher
than that of control group after OGTT of OSAS group,
particularly 2 h after OGTT. Figure 2 reveals curves of in-
sulin releasing tests of two groups; fasting insulin in OSAS
group was higher than in control group (16.5 ± 7.8 > 12.3 ±
7.3, P = 0.007). However, statistical significance was not
found in insulin levels of two groups after 30 min, 60 min,
120 min, 180 min of OGTT (P > 0.05). According to
OGTT-IRT, associated indicators for evaluation of insulin
resistance and B cell insulin releasing capacity include
HOMA-IR, Insulin secretion Index (HOME-B),whereas
differences in HOMA-IR and HOME-B of two groups
were not found to exist statistical significance (P > 0.05)





Table 2 Characteristics of recruited subjects
Control group Case group P
Subjects n 156 412 -
Sex ratio M:F 104/52 333/79 <0.001
Age yrs 42.15 ± 8.81 46.31 ± 9.99 <0.001
SBP mmHg 144.02 ± 15.67 146.04 ± 16.16 0.231
DBP mmHg 99.52 ± 10.29 99.76 ± 11.54 0.838
BMI kg/m2 26.22 ± 3.45 28.24 ± 3.53 <0.001
Neck circumferencecm 38.17 ± 5.22 40.99 ± 4.20 0.030
abdomen circumference cm 93.21 ± 9.69 99.75 ± 9.23 <0.001
hemoglobin 146.80 ± 15.42 148.42 ± 14.83 0.307
hs-CRP 1.45 ± 1.94 2.45 ± 3.94 0.008
FPG 5.02 ± 0.89 5.39 ± 1.47 0.010
total carbon dioxide 24.32 ± 2.63 24.90 ± 2.61 0.038
CHOL 4.40 ± 0.72 4.56 ± 0.88 0.079
TG 1.87 ± 0.47 2.35 ± 0.64 0.002
LDL-C 2.49 ± 0.61 2.54 ± 0.69 0.446
HDL-C 1.18 ± 0.32 1.11 ± 0.30 0.012
CHOL/HDL-C 3.96 ± 1.06 4.36 ± 1.27 0.001
hs-CRP: high-sensitivity C-reactive protein; FPG: fasting peripheral glucose;
CHOL: total cholesterol; TG: triglyceride; LDL-C: low-density lipoprotein
cholesterol ;HDL-C: high-density lipoprotein cholesterol.
Figure 2 The level of insulin release test between
case-control group.
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Before association analysis, all SNPs were subjected to
Hardy Weinberg Equilibrium(HWE) which suggested that
genotypes of all SNPs were in HWE proportions and none
of the SNPs was deviated from HWE. Total number of sub-
jects is 568, with 11 genotyping failure. Difference between
SNPrs5417genotype frequency and allele frequency dis-
tribution was statistically significant between case group
(405 cases) and control group (152 cases). Statistic differ-
ence was found between gene frequency and allele fre-
quency and GLUT4gene SNPrs5417 in males afterFigure 1 The level of OGTT between case-control group.gender-stratified analysis (P < 0.05), but the difference
does not exist in female subjects. No association was
found between rs5415 and rs5435 locus of GLUT4
gene and OSAS (P > 0.05) (Shown in Table 3).Haploid type of GILU4 gene polymorphism locus in two
groups
SNP analyzer software was used to analyze Matching link-
age disequilibrium analysis and haplotype separate analysis
of three locus of GLUT4 gene, and D′ was found to be
0.9, suggesting rs5417, rs5415 and rs5435 locus were in
incomplete linkage disequilibrium in our study subjects,
which needs further separate analysis. Most frequent vari-
able sites, SNP r5415, rs5417 and rs5435, can constitute 6
haplotypes, of which frequencies > 4% are 4 types. Most
common haplotypes account for 96.64% of haplotypes
in OSAS patients, and statistically significant difference
was found in distribution of H1 (rs5415T-rs5417C-
rs5435C) and H3 (rs5415C-rs5417C- rs5435C) in two
groups (P < 0.05), and frequencies of C haplotype in
case group were higher than in controls (shown in
Table 4).Figure 3 Compare of HOMA-IR and HOME-B Index between
case-control group.
Table 3 Genotype and allele distributions for three polymorphisms of GLUT4 in control and in patients with OSAS
Polymorphisms Total Male Female
Genotypes Control n (%) OSAS group n (%) Control n (%) OSAS group n (%) Control n (%) OSAS group n (%)
rs5417 AA 28 (18.4) 53 (13.1) 22 (22.0) 46 (14.1) 6 (11.5) 7 (9.0)
AC 85 (55.9) 200 (29.4) 56 (56.0) 151 (46.2) 29 (55.8) 49 (62.8)
CC 39 (25.7) 152 (37.5) 22 (22.0) 130 (39.8) 17 (32.7) 22 (28.2)
Χ2 = 7.630, P = 0.022 Χ2 = 11.332,P = 0.003 Χ2 = 0.673, P = 0.714
A 141 (46.4) 306 (53.6) 100 (50.0) 243 (37.2) 41 (39.4) 63 (40.4)
C 163 (53.6) 504 (62.2) 100 (50.0) 411 (62.8) 63 (60.6) 93 (59.6)
Χ2 = 6.811, P = 0.009 Χ2 = 10.514, P = 0.001 Χ2 = 0.024, P = 0.877
CC 73 (48.0) 209 (51.4) 54 (52.9) 170 (51.7) 19 (38.0) 39 (50.0)
CT 67 (44.1) 154 (37.8) 40 (39.2) 120 (36.5) 27 (54.0) 34 (43.6)
TT 12 (7.9) 44 (10.8) 8 (7.8) 39 (11.9) 4 (8.0) 5 (6.4)
rs5415 Χ2 = 2.272, P = 0.321 Χ2 = 1.330,P = 0.514 Χ2 = 0.668, P = 0.716
C 213 (70.1) 572 (70.3) 148 (72.5) 460 (69.9) 65 (65.0) 112 (71.8)
T 91 (29.9) 242 (29.7) 56 (27.5) 198 (30.1) 35 (35.0) 44 (28.2)
Χ2 = 0.004, P = 0.947 Χ2 = 0.522,P = 0.470 Χ2 = 1.319, P = 0.251
CC 66 (43.7) 187 (46.4) 44 (44.4) 157 (47.9) 22 (42.3) 30 (40.0)
CT 71 (47.0) 169 (41.9) 48 (48.5) 128 (39.0) 23 (44.2) 41 (54.7)
TT 14 (9.3) 47 (11.7) 7 (7.1) 43 (13.1) 7 (13.5) 4 (5.3)
rs5435 Χ2 = 1.400, P = 0.497 Χ2 = 4.209, P = 0.122 Χ2 = 3.046 P = 0.218
C 203 (67.2) 543 (67.4) 136 (68.7) 542 (71.7) 67 (64.4) 101 (67.3)
T 99 (32.8) 263 (32.6) 62 (31.1) 214 (28.3) 37 (35.6) 49 (32.7)
Χ2 = 0.002, P = 0.962 Χ2 = 4.690, P = 0.406 Χ2 = 0.232, P = 0.630
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After adjusting such confounding factors of OSAS as gen-
der, age, body mass index (BMI) hemorrheologic and sleep
parameters using logistic regression, (AA +AC) genotype
was still an independent protective factor for OSAS
individuals (OR=0.362, 95%CI 0.159~0.823, P = 0.015).
Additionally male, more than 50 years, overweight,
obesity and lowest arterial oxygen saturation were sig-
nificant predictive factors associated with OSAS in-
dividuals comparing with controls (shown in Table 5).
Association analysis of GLUT4 rs5417 with OSAS-related
biochemical parameters
One-way association analysis between the mutated
locus and OSAS-related biochemical parameters andTable 4 Haplotype distributions for three polymorphisms
of GLUT4 in control and in patients with OSAS
Haplotype Overall (%) case (%) control (%) P
H1 T-C-C 38.28 36.28 4.37 0.025
H2 T-C-T 27.37 2.71 28.09 0.806
H3 C-C-C 26.75 28.58 21.77 0.024
H4 C-C-T 4.24 4.65 3.2 0.299PSG-related parameters found awake oxygen saturation
and minimal oxygen saturation in (AA + AC) genotype
superior to those in CC genotype in OSAS males of Han
population (P < 0.05), whereas average heart rate and sys-
tolic blood pressure in (AA +AC) genotype were lower
than in CC genotype (P < 0.05) (shown in Table 6).
Discussion
Our study first reports GLUT4 gene SNPrs5417 allele is
significantly associated with diagnosis of OSAS in hyper-
tensive population. In addition, significant association is
found between GLUT4 gene SNPrs5417 and males with
OSAS. A allelic frequency in case group is lower than in
control group. Significant relation is found between
GLUT4 gene and males with OSAS in Han population,
whereas the relation is not found in female subjects.
It is unanimously recognized that OSAS has familial ag-
gregation and genetic susceptibility; however its genetic
mechanism remains unknown so far. More than 72% in
our study subjects have hypertension coupled with OSAS,
and other epidemiological studies have indicated that
prevalence of OSAS in hypertensive population is up to
50% ~ 60% [22]. Hypertension and OSAS often coexist,
and our previous study found patients merging with OSAS





Wald DOF P OR
Value
95.0% C.I. for OR
Lower Upper
Tender(male) 0.836 0.238 12.384 1 0.000 2.307 1.448 3.676
Age(>50)years 0.796 0.245 10.568 1 0.001 2.217 1.372 3.582
BMI ≥ 24Kg/m2 1.022 0.323 10.022 1 0.002 2.779 1.476 5.234
Lowest arterial oxygen saturation 0.341 0.069 25.256 1 0.000 1.406 1.231 1.605
rs5417(AA + AC) −1.016 0.419 5.881 1 0.015 0.362 0.159 0.823
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ders [23,24]. These people are more likely to coexist insu-
lin resistance, increased triglyceride and uric acid levels
and decreased high density lipoprotein cholesterol. This
study eliminated confounding factors of hypertension in
OSAS patients by case–control design of particular sub-
jects. In OSA, cycles of hypoxia and re-oxygenation facili-
tate the formation of reactive oxygen species (ROS) which
impair endothelial function [25] and promote lipid and
glucose peroxidation [26,27] and increased formation of
ROS can activate inflammatory responses [28]. One of the
major sources of cellular reactive oxygen species (ROS)
is mitochondria, dysfunction of which contributes to
several pathological conditions including vascular com-
plications of diabetes, neurodegenerative diseases, and
cellular senescence. Shorter intermittent hypoxic expo-
sures as pathophysiology of OSAS might preferentially
activate inflammatory pathways and over-expression of
such inflammatory factors as TNF-α, IL-6 and IL-8 [29],
which influences normal insulin signaling of adipocytes
and GLUT4, bringing about reduction of glucose as-
similation triggering metabolic dysregulation [30]. Fur-
thermore, Insulin-stimulated GLUT4 translocation and
glucose uptake are associated with NF- KB activation
[31] which, a susceptible gene for OSAS [32] and nu-
clear receptor, plays a central role in inflammatory re-
sponse and orchestrates over-expression of a range of
factors including cytokines (TNF-a, IL-6 and IL-8) and
adhesion molecules (intercellular adhesion molecule-1)
[33,34]. Overwhelming findings emphasize we gain full
understanding about relation between OSAS andTable 6 Comparison of sleep parameters phenotype
among different genotypes of SNP in GLUT4 gene
rs5417 Genotype awake blood oxygen lowest blood oxygen





Beta values 0.823 0.540
Data are presented as mean ± SD unless otherwise stated. P values# and beta
values were adjusted simultaneously for age, gender and BMI by a general
linear regression.dysglycemia. In particular it is necessary to understand
hereditary susceptibility of OSA and glucose metabol-
ism. According to analysis of baseline data in this study,
concentrations of FPG and hypersensitive C-reactive
protein are higher in case group than in controls, indi-
cating coupling reactions of dysimmunity caused by
GLUT4 gene-related dysglycemia such as airway inflam-
matory cell invasion and high airway resistance leading
to hypopnea and apnea during sleep.
Sushmita [35] reported prevalence of OSAS in T2DM
is around 71%. IR acts as important role of pathogenesis
of T2DM [36]. Recently, total serum cholesterol/high-
density lipoprotein cholesterol as evaluation index of IR
has become a hotspot in cardiovascular diseases [37].
Present study found significant difference of insulin re-
sistance in OSAS patients comparing with controls using
assessment indicators. FPG and fasting insulin of OSAS
group was found to be higher than those of non-OSAS
group after OGTT and insulin releasing test, explaining
risk for impaired glucose tolerance of OSAS patients
was higher, impaired fasting glucose reflecting basal in-
sulin level secreted from β-cell is affected, and Punjabi
[38] showed that severe OSAS is associated with func-
tion of pancreatic B cells. The two indicate intermittent
hypoxia and re-oxygenation during OSAS bring about
elevation of ROS. β cell is sensitive to ROS which gener-
ates dysfunction of β cell and even apoptosis. Therefore
we can assume patients with OSAS experience a peak of
ROS after nocturnal hypoxia, which affects β cell signifi-
cantly, whereas intermittent hypoxia hardly exist day-
time; thus there is no difference in dawn FPG and
insulin levels of OSAS and non OSAS group. This is also
the reason why dawn blood pressure is monitored in order
to evaluate responsiveness of CPAP therapy; meanwhile
this can explain why no significant differences are found
in FPG and insulin levels of OSAS and non OSAS groups
after activity and oxygen intake increasing. However β-cell
damage increases with progress and severity of OSAS, and
type 2 diabetes mellitus develops finally.
GLUT4 is an insulin-dependent glucose transporter
protein, playing a pivotal part on IR by insulin signaling
pathway [39]. P38MAPK signaling pathway may improve
insulin sensitivity through increasing intrinsic activity of
GLUT4 and consequently increase glucose transportation
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p-p38MAPK and GLUT4 gene expression increased in IR
rats of animal models. The latest study revealed P38MAPK
is sensitive to ROS [43]. Reduction of P38MAPK activity
reduces tolerance of brain to anoxia [44]. Intermittent
hypoxia, the hallmark of OSAS, is implicated to promote
formation of ROS and to induce oxidative stress, and
brings about metabolic disorders such as hypertension,
T2DM, insulin resistance, which aggregates OSAS. A
part from inhibiting P38 MAPK, hypoxia also inhibits
Akt-mTOR in differentiating myoblasts [45]. Rena′s
[46] research confirmed genetic and pharmacological
evidence suggesting that suppression of Akt and mTOR
activity is responsible for the loss of the myogenic ac-
tion of insulinlike growth factors under hypoxia. Some
other evidences indicate that selective suppression of
PI3K/Akt /mTOR signaling pathway supresses inflam-
matory reaction caused by oxidative stress [47]. Except
for this, reduction of antioxidant enzymes in pancreas β
cell is both an important target spot of ROS [48], and a
direct factor of OSAS to generate IR. An observational
cohort study found remarkable improvement of fasting
and postprandial glucose in moderate to severe OSAS
patients without obesity after CPAP therapy [49]. Thus
we can infer chronic oxidative stress secondary to OSAS
and excessive reactive oxygen species influence activa-
tion of correlative signaling pathway and nuclear recep-
tor to lead to abnormal activation and expression of
GLUT4 gene. Treatment of OSAS contributes to regu-
late activity of reflective signaling pathway, increase
activation of GLUT4 molecule, improve IR in OSAS
patients, and decrease cardiovascular events.
Moreover, SNPrs5417 subtype of GLUT4 gene related to
OSAS expressed significant difference in gender; C allelic
of male case group was significantly higher than that of
male control group, whereas this phenomenon does not
exist in female subjects. Some animal experiments reported
that melting GLUT4 of musculi soleus in male rats causes
reduction of ATP and phosphocreatine, which is more
obvious than those of female rats [50]. GLUT4 mainly
serves as its glucose transporter in skeletal muscle and
liver, difference of which in males and females may bring
about different expression in the same environment after
influenced by intermittent hypoxia. However, a recent
Turkish study reported OSAS-induced inflammation is
more obvious in females [51]. Prevalence of OSAS is dom-
inant in males; clinical studies have been focused on males,
which has lead to lack of data on females. This study did
not find any relation between three locus’ mutation of
GLUT4 and OSAS in female subjects, which may have
some connections with sample size and racial difference.
This aspect needs further molecular researches and lon-
gitudinal, large-sampled, population-based studies to ex-
plore. AA and AC types of SNP rs5417 were found to beindependent protective factors for OSAS susceptibility,
compared with CC type after adjustments for confounding
factors using logistic regression analysis. Awake oxygen
saturation and minimal oxygen saturation are higher in
carriers of (AA + AC) types of GLUT4 rs5417 than in
CC Homozygote types in male subjects with OSAS of
Han population, which is consistent with findings from
other studies. This result explains anoxia in C allelic
carriers is more severe; although there is no difference
in AHI of recessive genetic model, severity of OSAS in
CC type carriers can be inferred. Since OSAS is a com-
plex disease caused by genetic and environmental inter-
action, single mutation locus of GLUT4 is not sufficient
to bring about intermediate phenotype and Phenotype
change of OSAS. No association has been found be-
tween rs5415 and rs5435 gene types and OSAS, whereas
haplotypes of combinations of rs5417, rs5415 and
rs5435 reported to be associated with OSAS. Nair [52]
ect found combined haplotypes of rs5417 and rs5418 of
GLUT4 gene and combined haplotypes of rs5435 and
rs5415 associated with T2DM. It is obvious that com-
bination of GLUT4 gene and TaqSNPs increases genetic
susceptibilities of OSAS and its related clinical co-
morbidities.
Conclusions
To take aforementioned evidences together, SNPrs5417
of GLUT4 gene is correlated to OSAS; Awake oxygen
saturation and minimal oxygen saturation in AA homo-
zygote of GLUT4 SNPrs5417 in Han population are
higher than in CC homozygote. Elaborate regulations of
cellular pathways related to GLUT4 and OSAS needs
further explorations, and extension of GLUT4 genes




Patients hospitalized in the center of hypertension diag-
nosis and treatment of People’s Hospital of Xinjiang
Uygur Autonomous Region from January to December
2010 were selected, based on following exclusive and in-
clusive criteria. Exclusive criteria: subjects with a history
of long-term alcohol-intake, asthma, bronchiectasia, se-
vere maxillofacial deformities, thyroid diseases, chronic
obstructive pulmonary diseases, acute phase of infection,
history of upper-airway surgery, history of pancreas
surgery, pheochromocytoma, primary hyperaldosteron-
ism, established T2DM or taking hypoglycaemic drugs,
cerebro-cardiovascular diseases within 6 months, se-
vere hetapic and/or renal diseases and cancer were
excluded from this study. Inclusive criteria: patients
who had nocturnal snoring, apneas, diurnal sleepiness
during reading, watching TV, or meetings lasting at
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medical history and physical examination; hypertensive
patients with unexplained lip and/or tongue dryness,
unexplained cyanosis of lip and/or nail bed, elevation
of hemoglobin levels and/or hematocrit. A total of 568
Han Chinese with no miscegenation satisfied above
inclusive criteria and underwent polysomnography (PSG),
412 (133 mild OSAS, 141moderate OSAS and 138 se-
vere OSAS) of whom were diagnosed with OSAS and
selected as case group on the basis of apnea-hypopnea
index (AHI ≥ 5); 156 of 568 were determined to have no
OSAS according to apnea-hypopnea index (AHI < 5)
and selected as control group. Study protocol was ap-
proved by Ethic’s Committees of Health Ministry in
Xinjiang Uygur Autonomous Region, and People’s Hos-
pital of Xinjiang Uygur Autonomous Region; informed
consent was signed by all subjects.
Data collection
Baseline data of subjects were collected and completed
immediately after their hospitalization by physicians.
Questionnaire contents included age, gender, height,
weight, waist circumference, heart rate, blood pressure
and other general information, diagnosis or treatment
history of hypertension, hypercholesterolemia, and DM.
BMI was calculated by weight in Kg divided by height in
squared meter. Fasting blood samples were collected from
median cubital veins of each subjects after overnight PSG
at sleep monitoring center in order to be used for analysis
of liver and renal function, FPG, serum and urinary elec-
trolytes, and blood lipids.
PSG
Polysomnography (PSG) was recorded using (computer
E system Australian). Sleep studies were performed in a
dedicated, quiet, dark room. Nocturnal sleep duration was
at least 7 hours for monitoring. No sleep deprivation,
caffeine, sedation or alcohol was used. Monitoring Param-
eters included electroencephalography (EEG), electro-ocu-
lography (EOG) and electromyography (EMG), EEG was
recorded from two scalp sites (Cz/Pz). Frontal EEG was
also recorded using “mixed” channels comprising EEG/
EOG signals (Cz/Fp1, Cz/Fp2). EOG was recorded from
electrodes placed at sites on the outer canthus of the eye.
Submental EMG was recorded using two electrodes
placed on the belly of the genioglossus. A grounding
electrode was placed at Fpz. Electrodes placed on the
right and left anterior tibialis recorded leg EMG. Nasal
oxygen catheter was used for recording oro-nasal
airflow, body position and chest wall movement by elec-
trical impedance, heart rate using an electrocardiogram
and finger pulse oximetry. All signals were recorded on
computer. Data were analysed by a specialized re-
searcher (Yingchun Wang) after blinding of data usingAASM scoring manual. Standard criteria [53]: ①apneas:
complete oro-nasal apneas continuing more than 10s.
②hypopneas:air flow decreasing more than 50% and
oxygen saturation more than 4% from baseline values,
continuing over 10 seconds. ③apnea-hypopnea index,
AHI = (apnea events + hypopnea events)/h.
GLUT4 gene sequencing and polymorphism detection
We sequenced all exons and the promoter region of
GLUT4 gene. Blood samples were obtained from 96
(male 84,female 12) severe OSAS cases, who were
chosen from OSAS group of the study population.
Reagent-Kit was used to extract DNA from blood sam-
ples using phenol-chloroform extraction (PAXgene
blood DNA Kit, A Q IAGEN /BD Company). Total
region of exons with their flanking sequences and ap-
proximately 1.0 kb of the upstream region had PCR
amplification and sequencing analysis (ABI 3130x,lB
igDye Term inator Cycle sequencing V311 /V111 K it,
Applied Biosystems, Foster City, Californ ia, USA). The
designable set of common SNPs (minor allele frequency
>5%) were genotyped in common variable sites of Han
Chinese population through Sequencing. Representative
mutated loci was selected according to linkage disequilib-
rium (LD) (r2 > 0.8). TaqMan- PCR (ABI PRISM7900HT
Sequence Detection System, Warrington, UK) was used to
determine genotypes. Reaction system of TaqMan-PCR:
Master Mix 2.25 uL, Primer 0.125 uL, DNA 1.0 uL, plus
deionized water until 5uL.Reaction condition of TaqMan-
PCR:Initial denaturation 95°C 10 min, 43 cycle (dege-
neration 95°C15 s, annealing 60°C1 min, extension 71°C
1 min), extension 72°C 7 min. Quality control of geno-
types was as following: blank and positive comparison was
set for every 384, and case samples were randomly distrib-
uted. Read ratio Of genotypes is > 98%; concordance rate
of duplicate detectionis is 100%. TaqMan PCR genotyping
probe of mutation loci and primer information reported at
database were acquired from US biological systems web
site (http://appliedbiosystems.com).
Statistical analysis
Before carrying out tests for association, all SNPs were
tested for Hardy-Weinberg Equilibrium (HWE). SNP
analyzer software was used for testing for linkage dis-
equilibrium, haplotype analysis and genotype frequency
calculation. Computer package IBM SPSS Statistical
version 19 was used for statistical analysis. Data were
presented as proportions, means (±SD), geometric
means (SD range), or, in the case of variables that did
not conform to a normal or log-normal distribution,
medians (interquartile range). For independent samples,
proportions by Fisher’s exact tests were used for two-
way comparison, for normally distributed variables in-
dependent sample t test was used, and for nonnormally
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Tests for association were normally done by Chi-square
test for testing difference in gene frequency and allele
frequency. Logistic regression analysis was used to deter-
mine whether plausible mediating or confounding vari-
ables were independently associated with outcome.
Tests for association of genotypes with biochemical pa-
rameters and parameters related to sleep were done by
analysis of One-way ANOVA. All p-values were for
two-tailed tests and considered to be significant at a
0.05 level.
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